Advertisement
Canada markets closed

  • S&P/TSX

    22,465.37
    +165.54 (+0.74%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.21 (+0.34%)
     

  • CAD/USD

    0.7348
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     

  • Bitcoin CAD

    90,950.59
    +1,867.52 (+2.10%)
     

  • CMC Crypto 200

    1,364.66
    -9.18 (-0.67%)
     

  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     

  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     

  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     

  • NASDAQ

    16,685.97
    -12.35 (-0.07%)
     

  • VOLATILITY

    11.99
    -0.43 (-3.46%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • CAD/EUR

    0.6755
    -0.0001 (-0.01%)
     

DiaSorin confirms 2023 guidance after Q1 results

Reuters
·1 min read

(Reuters) - Italian medical diagnostics group DiaSorin said on Wednesday it had reported a decline in revenue in the first quarter, after demand in COVID-related business sharply dropped as pandemics effects faded away.

Q1 revenue plunged 20.6% year-on-year to 289.6 million euros ($318.79 million), leading to a 40.6% shrink in net profit, which came in at 41.7 million euros, the company said in a note.

Revenue from COVID-related business unit dropped 78.5% in the first quarter, in line with an expected 75% decrease year-on year. Net of this unit and molecular respiratory business, revenue grew 3% at constant perimeter.

DiaSorin confirmed its 2023 guidance for the full year, which sees total revenue down 14% on a yearly basis.

($1 = 0.9084 euros)

(Reporting by Alberto Chiumento in Gdansk; Editing by Cristina Carlevaro)